Pacific Biosciences
PACB
94 hedge funds and large institutions have $230M invested in Pacific Biosciences in 2015 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 32 increasing their positions, 29 reducing their positions, and 19 closing their positions.
10% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 29
7% less funds holding
Funds holding: 101 → 94 (-7)
32% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 19
33% less capital invested
Capital invested by funds: $342M → $230M (-$112M)
34% less call options, than puts
Call options by funds: $107K | Put options by funds: $162K
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
Top Sellers
| 1 |
DM
Deerfield Management
New York
|
-$14.3M |
| 2 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$2.57M |
| 3 |
D.E. Shaw & Co
New York
|
-$2.47M |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$1.95M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
-$1.87M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
Citadel Advisors
Miami,
Florida
| – | -$327K | -41,659 | Closed |
|
|
CIA
102
Capital Impact Advisors
Boston,
Massachusetts
| – | -$207K | -26,437 | Closed |
|
|
PP
103
Paloma Partners
Greenwich,
Connecticut
| – | -$180K | -22,900 | Closed |
|
104
Squarepoint
New York
| – | -$176K | -22,400 | Closed |
|
105
William Blair & Company
Chicago,
Illinois
| – | -$164K | -21,000 | Closed |
|
106
SG Americas Securities
New York
| – | -$122K | -15,603 | Closed |
|
|
LTFS
107
Ladenburg Thalmann Financial Services
Miami,
Florida
| – | -$110K | -14,000 | Closed |
|
|
EMG
108
Ellington Management Group
Old Greenwich,
Connecticut
| – | -$78K | -10,000 | Closed |
|
|
FNBT
109
FineMark National Bank & Trust
Fort Myers,
Florida
| – | -$55K | -7,000 | Closed |
|
|
GT
110
Glenmede Trust
Philadelphia,
Pennsylvania
| – | -$54K | -7,000 | Closed |
|
|
QT
111
Quantbot Technologies
New York
| – | -$32K | -4,097 | Closed |
|
|
PCM
112
Prelude Capital Management
New York
| – | -$26K | -3,256 | Closed |
|
|
TRCT
113
Tower Research Capital (TRC)
New York
| – | -$2K | -200 | Closed |
|
PACB Hedge Fund Activity: Q1 2015 in Review
94 of the 3,752 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q1 2015, worth a combined $230M — down 33% from $342M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of PACB and 13 opened new positions — a net loss of 6 holders — while 29 trimmed existing stakes and 32 added.
The largest buyer was Consonance Capital Management, opening a new position worth an estimated $13.8M. The largest seller was Deerfield Management, cutting an estimated $14.3M.
- 94 institutional investors held Pacific Biosciences (PACB) as of Q1 2015, down from 101 in Q4 2014.
- Funds reported $230M of Pacific Biosciences stock for Q1 2015, down 33% quarter-over-quarter.
- 13 funds opened new Pacific Biosciences positions in Q1 2015 and 19 closed out, a net change of -6 holders.
- The largest Pacific Biosciences buyer in Q1 2015 was Consonance Capital Management, an estimated $13.8M added.
- The largest Pacific Biosciences seller in Q1 2015 was Deerfield Management, an estimated $14.3M sold.
Based on aggregated 13F filings for Q1 2015.